Karyopharm Therapeutics Inc. and Clinipace Worldwide Announce Preferred Provider Agreement

Clinipace Worldwide announced it has entered into a preferred provider agreement with Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The preferred provider agreement is part of a longer-term strategic partnership that would see Clinipace managing several clinical programs, including oncology, wound healing, and other diseases, on behalf of Karyopharm in 2014.

Read the full release here.